Citation: | HUANG Jian-yu, WANG Yong-ming, WANG Ruo-ning, DI Liu-qing. Preparation and in vivo and vitro Evaluation of pH-Sensitive Liposomes Loading Arsenic Trioxide[J]. Journal of Nanjing University of traditional Chinese Medicine, 2021, 37(3): 404-410. doi: 10.14148/j.issn.1672-0482.2021.0404 |
[1] |
李时珍. 本草纲目[M]. 影印本. 北京: 中国书店, 1988: 21.
|
[2] |
LO-COCO F, AVVISATI G, VIGNETTI M, et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia[J]. N Engl J Med, 2013, 369(2): 111-121. doi: 10.1056/NEJMoa1300874
|
[3] |
SADAF N, KUMAR N, ALI M, et al. Arsenic trioxide induces apoptosis and inhibits the growth of human liver cancer cells[J]. Life Sci, 2018, 205: 9-17. doi: 10.1016/j.lfs.2018.05.006
|
[4] |
SUN YY, WANG C, WANG LG, et al. Arsenic trioxide induces apoptosis and the formation of reactive oxygen species in rat glioma cells[J]. Cell Mol Biol Lett, 2018, 23: 13. doi: 10.1186/s11658-018-0074-4
|
[5] |
HUANG DL, WANG YT, XU LL, et al. GLI2 promotes cell proliferation and migration through transcriptional activation of ARHGEF16 in human glioma cells[J]. J Exp Clin Cancer Res, 2018, 37(1): 247. doi: 10.1186/s13046-018-0917-x
|
[6] |
WU JN, JI ZY, LIU HL, et al. Arsenic trioxide depletes cancer stem-like cells and inhibits repopulation of neurosphere derived from glioblastoma by downregulation of Notch pathway[J]. Toxicol Lett, 2013, 220(1): 61-69. doi: 10.1016/j.toxlet.2013.03.019
|
[7] |
DING DC, LIM KS, EBERHART CG. Arsenic trioxide inhibits Hedgehog, Notch and stem cell properties in glioblastoma neurospheres[J]. Acta Neuropathol Commun, 2014, 2: 31. doi: 10.1186/2051-5960-2-31
|
[8] |
RAJU GP. Arsenic: A potentially useful poison for Hedgehog-driven cancers[J]. J Clin Invest, 2011, 121(1): 14-16. doi: 10.1172/JCI45692
|
[9] |
KIM J, LEE JJ, KIM J, et al. Arsenic antagonizes the Hedgehog pathway by preventing ciliary accumulation and reducing stability of the Gli2 transcriptional effector[J]. Proc Natl Acad Sci USA, 2010, 107(30): 13432-13437. doi: 10.1073/pnas.1006822107
|
[10] |
COHENKJ, GIBBS IC, FISHER PG, et al. A phase Ⅰ trial of arsenic trioxide chemoradiotherapy for infiltrating astrocytomas of childhood[J]. Neuro Oncol, 2013, 15(6): 783-787. doi: 10.1093/neuonc/not021
|
[11] |
KUMTHEKAR P, GRIMM S, CHANDLER J, et al. A phase Ⅱ trial of arsenic trioxide and temozolomide in combination with radiation therapy for patients with malignant gliomas[J]. J Neurooncol, 2017, 133(3): 589-594. doi: 10.1007/s11060-017-2469-x
|
[12] |
VINEETHA VP, RAGHU KG. An overview on arsenic trioxide-induced cardiotoxicity[J]. Cardiovasc Toxicol, 2019, 19(2): 105-119. doi: 10.1007/s12012-018-09504-7
|
[13] |
ALEXANDRE J, MOSLEHI JJ, BERSELL KR, et al. Anticancer drug-induced cardiac rhythm disorders: Current knowledge and basic underlying mechanisms[J]. Pharmacol Ther, 2018, 189: 89-103. doi: 10.1016/j.pharmthera.2018.04.009
|
[14] |
ZHAO PF, WANG YH, KANG XJ, et al. Dual-targeting biomimetic delivery for anti-glioma activity via remodeling the tumor microenvironment and directing macrophage-mediated immunotherapy[J]. Chem Sci, 2018, 9(10): 2674-2689. doi: 10.1039/C7SC04853J
|
[15] |
LIU S, ZHANG SM, JU RJ, et al. Antitumor efficacy of Lf modified daunorubicin plus honokiol liposomes in treatment of brain glioma[J]. Eur J Pharm Sci, 2017, 106: 185-197. doi: 10.1016/j.ejps.2017.06.002
|
[16] |
YANG ZZ, LI JQ, WANG ZZ, et al. Tumor-targeting dual peptides-modified cationic liposomes for delivery of siRNA and docetaxel to gliomas[J]. Biomaterials, 2014, 35(19): 5226-5239. doi: 10.1016/j.biomaterials.2014.03.017
|
[17] |
陈云云, 姚文栋, 谢先泽, 等. 载As2O3 pH敏感钙砷复合物脂质体的制备及体外评价[J]. 中草药, 2020, 51(21): 5447-5453. doi: 10.7501/j.issn.0253-2670.2020.21.008
|
[18] |
GARCIA-HEVIA L, BANOBRE-LOPEZ M, GALLO J. Recent progress on manganese-based nanostructures as responsive MRI contrast agents[J]. Chemistry, 2019, 25(2): 431-441. doi: 10.1002/chem.201802851
|
[19] |
ZHAO Z, WANG X, ZHANG Z, et al. Real-time monitoring of arsenic trioxide release and delivery by activatable T(1) imaging[J]. ACS Nano, 2015, 9(3): 2749-2759. doi: 10.1021/nn506640h
|
[20] |
FEI W, ZHANG Y, HAN S, et al. RGD conjugated liposome-hollow silica hybrid nanovehicles for targeted and controlled delivery of arsenic trioxide against hepatic carcinoma[J]. Int J Pharm, 2017, 519(1/2): 250-262. http://europepmc.org/abstract/med/28109899
|
[21] |
XIN JY, ZHANG K, HUANG JQ, et al. Facile synthesis of aquo-cisplatin arsenite multidrug nanocomposites for overcoming drug resistance and efficient combination therapy[J]. Biomater Sci, 2018, 7(1): 262-271. http://www.onacademic.com/detail/journal_1000041602659799_2f3e.html
|
[22] |
FAN LH, LIU C, HU AZ, et al. Dual oligopeptides modification mediates arsenic trioxide containing nanoparticles to eliminate primitive chronic myeloid leukemia cells inside bone marrow niches[J]. Int J Pharm, 2020, 579: 119179. doi: 10.1016/j.ijpharm.2020.119179
|
[23] |
ZHANG K, LIN HY, MAO JJ, et al. An extracellular pH-driven targeted multifunctional manganese arsenite delivery system for tumor imaging and therapy[J]. Biomater Sci, 2019, 7(6): 2480-2490. doi: 10.1039/C9BM00216B
|
[24] |
ZHANG Q, VAKILI MR, LI XF, et al. Polymeric micelles for GSH-triggered delivery of arsenic species to cancer cells[J]. Biomaterials, 2014, 35(25): 7088-7100. doi: 10.1016/j.biomaterials.2014.04.072
|
[25] |
马瑞, 汤红霞, 陆燕平, 等. 氧化还原响应性二氧化硅载三氧化二砷纳米递药系统的制备及体外评价[J]. 中草药, 2020, 51(6): 1508-1516. https://www.cnki.com.cn/Article/CJFDTOTAL-ZCYO202006018.htm
|
[26] |
GUO ST, MIAO L, WANG YH, et al. Unmodified drug used as a material to construct nanoparticles: Delivery of cisplatin for enhanced anti-cancer therapy[J]. J Control Release, 2014, 174: 137-142. doi: 10.1016/j.jconrel.2013.11.019
|
[27] |
GUO ST, WANG YH, MIAO L, et al. Lipid-coated Cisplatin nanoparticles induce neighboring effect and exhibit enhanced anticancer efficacy[J]. ACS Nano, 2013, 7(11): 9896-9904. doi: 10.1021/nn403606m
|